WO2010038974A3 - 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트 - Google Patents

이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트 Download PDF

Info

Publication number
WO2010038974A3
WO2010038974A3 PCT/KR2009/005589 KR2009005589W WO2010038974A3 WO 2010038974 A3 WO2010038974 A3 WO 2010038974A3 KR 2009005589 W KR2009005589 W KR 2009005589W WO 2010038974 A3 WO2010038974 A3 WO 2010038974A3
Authority
WO
WIPO (PCT)
Prior art keywords
nephropathy
tgbm
urine
protein
iga nephropathy
Prior art date
Application number
PCT/KR2009/005589
Other languages
English (en)
French (fr)
Other versions
WO2010038974A2 (ko
WO2010038974A9 (ko
Inventor
백문창
문평곤
김용림
Original Assignee
경북대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 경북대학교 산학협력단 filed Critical 경북대학교 산학협력단
Priority to US13/002,224 priority Critical patent/US8927220B2/en
Publication of WO2010038974A2 publication Critical patent/WO2010038974A2/ko
Publication of WO2010038974A3 publication Critical patent/WO2010038974A3/ko
Publication of WO2010038974A9 publication Critical patent/WO2010038974A9/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/5436—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand physically entrapped within the solid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
    • G01N2001/4083—Concentrating samples by other techniques involving separation of suspended solids sedimentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4713—Plasma globulins, lactoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8125—Alpha-1-antitrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90287—Oxidoreductases (1.) oxidising metal ions (1.16)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/973—Simultaneous determination of more than one analyte
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Organic Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Genetics & Genomics (AREA)

Abstract

본 발명은 타겟 프로테오믹스 기법으로 뇨를 이용한 IgA 신증과 TGBM(thin-glomerular-basement-membrane)의 진단 바이오마커로 사용 될 수 있는 단백질 개발에 관한 것으로서, 정상인의 뇨에서 보다 IgA 신증와 TGBM 신증 환자의 뇨에서 그 양이 증감되어지는 진단 바이오마커 단백질과 이를 이용한 IgA 신증과 TGBM의 진단 및 진행정도를 미리 예견하는 키트에 관한 것이다. 본 발명에 따르면, 사람의 뇨로부터 IgA 신증과 TGBM의 발병여부, 조기진단 및 진행정도를 확인하여 그 증상의 경도를 파악할 수도 있다. 또한 본 발병의 진단 바이오마커 단백질을 기초로 제조된 단일클론항체는 immunoassay 키트(ELISA, antibody coated tube test, lateral-flow test, potable biosensor)에 이용될 수 있을 뿐만 아니라, IgA 신증의 조기진단 및 진행정도를 판단하고, 치료용 목적으로는 신약 개발에 사용되어 질수 있다.
PCT/KR2009/005589 2008-10-01 2009-09-30 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트 WO2010038974A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/002,224 US8927220B2 (en) 2008-10-01 2009-09-30 Method for diagnosing immunoglobulin A nephropathy and TGBM nephropathy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0096862 2008-10-01
KR1020080096862A KR100928403B1 (ko) 2008-10-01 2008-10-01 티지비엠 신증의 진단용 조성물 및 키트

Publications (3)

Publication Number Publication Date
WO2010038974A2 WO2010038974A2 (ko) 2010-04-08
WO2010038974A3 true WO2010038974A3 (ko) 2010-08-26
WO2010038974A9 WO2010038974A9 (ko) 2010-11-04

Family

ID=41605396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/005589 WO2010038974A2 (ko) 2008-10-01 2009-09-30 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트

Country Status (3)

Country Link
US (1) US8927220B2 (ko)
KR (1) KR100928403B1 (ko)
WO (1) WO2010038974A2 (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2957704A1 (en) 2004-01-21 2005-08-04 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining a graft tolerant phenotype in a subject
WO2006099421A2 (en) 2005-03-14 2006-09-21 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
USRE46843E1 (en) 2005-03-14 2018-05-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
EP2324129A4 (en) 2008-08-18 2012-06-20 Univ Leland Stanford Junior METHODS AND COMPOSITIONS FOR DETERMINING A TOLERANT PHENOTYPE IN A GRAFT IN A SUBJECT
ES2492498T3 (es) 2009-01-15 2014-09-09 The Board Of Trustees Of The Leland Stanford Junior University Panel de biomarcadores para el diagnóstico y la predicción de rechazo de injerto
EP3185013B1 (en) 2009-12-02 2019-10-09 The Board of Trustees of the Leland Stanford Junior University Biomarkers for determining an allograft tolerant phenotype
CA2794255C (en) 2010-03-25 2020-01-14 Minnie M. Sarwal Protein and gene biomarkers for rejection of organ transplants
US9598733B2 (en) 2011-02-17 2017-03-21 The Trustees Of Columbia University In The City Of New York Methods for identifying subjects with a genetic risk for developing IgA nephropathy
US8962261B2 (en) 2011-04-06 2015-02-24 The Board Of Trustees Of The Leland Stanford Junior University Autoantibody biomarkers for IGA nephropathy
JP5777149B2 (ja) * 2011-04-27 2015-09-09 国立大学法人 宮崎大学 糸球体濾過膜の異常に関連した疾患の検査方法、およびこれに使用するための検査用キット
EP2877214B1 (en) * 2012-07-26 2019-04-24 Joslin Diabetes Center, Inc. Predicting diabetic complications
JP2015524926A (ja) * 2012-08-03 2015-08-27 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
US10202647B2 (en) 2013-04-12 2019-02-12 The Trustees Of Columbia University In The City Of New York Mutations in DSTYK cause dominant urinary tract malformations
EP3469372B1 (en) 2016-06-10 2023-03-08 Warszawski Uniwersytet Medyczny Methods for diagnosis and monitoring using urine proteins as markers in iga nephropathy
WO2018129056A1 (en) 2017-01-04 2018-07-12 The Research Foundation For The State University Of New York Biomarker detection device
EP3358355B1 (en) 2017-02-04 2023-10-11 Warszawski Uniwersytet Medyczny Use of serum 2-cysteine peroxiredoxins (2-cys-prdx) as biomarkers of chronic kidney diseases (ckd) such as lupus nephritis (ln), iga nephropathy (igan) and autosomal-dominant polycystic kidney disease (adpkd) useful for diagnosing, these diseases and method of differentiation of these diseases
WO2021152370A1 (en) 2020-01-31 2021-08-05 Warszawski Uniwersytet Medyczny Method of screening for a chronic kidney disease or glomerulopathy, method of monitoring a response to treatment of a chronic kidney disease or glomerulopathy in a subject and a method of treatment of a chronic kidney disease or glomerulopathy
US20230152333A1 (en) 2020-01-31 2023-05-18 Warszawski Uniwersytet Medyczny Method of differentiating of a chronic kidney disease or glomerulopathy, method of monitoring a response to treatment of a chronic kidney disease or glomerulop athy in a subject and a method of treatment of a chronic kidney disease or glomerulopathy
CN114324887A (zh) * 2021-10-14 2022-04-12 深圳市华启生物科技有限公司 免疫球蛋白a肾病t细胞诊断标志物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024899A1 (fr) * 1996-12-05 1998-06-11 Kyowa Hakko Kogyo Co., Ltd. GENE ASSOCIE A LA GLOMERULONEPHRITE A DEPOTS MESANGIAUX D'IgA
WO2000078788A1 (en) * 1999-06-24 2000-12-28 Gene Logic, Inc. NOVEL cDNA ASSOCIATED WITH RENAL DISEASE
WO2007082586A1 (en) * 2006-01-20 2007-07-26 Mosaiques Diagnostics And Therapeutics Ag Method and markers for the diagnosis of renal diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838634B2 (en) * 2005-04-15 2010-11-23 Van Andel Research Institute Methods for measuring glycan levels of proteins
TWI338779B (en) * 2005-07-21 2011-03-11 Academia Sinica Methods,compositions and systems for assaying at least one target analyte in a sample
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024899A1 (fr) * 1996-12-05 1998-06-11 Kyowa Hakko Kogyo Co., Ltd. GENE ASSOCIE A LA GLOMERULONEPHRITE A DEPOTS MESANGIAUX D'IgA
WO2000078788A1 (en) * 1999-06-24 2000-12-28 Gene Logic, Inc. NOVEL cDNA ASSOCIATED WITH RENAL DISEASE
WO2007082586A1 (en) * 2006-01-20 2007-07-26 Mosaiques Diagnostics And Therapeutics Ag Method and markers for the diagnosis of renal diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
UEDA, T. ET AL.: "Quantitative analysis of glomerular type IV collagen alpha 3-5 chain expression in children with thin basement membrane disease.", NEPHRON, vol. 92, no. 2, October 2002 (2002-10-01), pages 271 - 278 *

Also Published As

Publication number Publication date
WO2010038974A2 (ko) 2010-04-08
US8927220B2 (en) 2015-01-06
WO2010038974A9 (ko) 2010-11-04
KR100928403B1 (ko) 2009-11-26
US20110236913A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
WO2010038974A3 (ko) 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트
WO2007092627A3 (en) Detection of cancer by elevated levels of bcl-2
US10996217B2 (en) Method for examining renal disease
NO20076656L (no) Forbedrede immunoassay metoder
JP2008529008A5 (ko)
JP2012509477A5 (ko)
AR063125A1 (es) Ensayo elisa para la deteccion de vegf
WO2010057184A3 (en) Methods for detection of acute kidney injury in humans
AU2014269961A1 (en) Pathway specific markers for diagnosing irritable bowel syndrome
NZ619883A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN111183360A (zh) 同时评估非酒精性脂肪性肝炎和肝纤维化状态的生物标志物组合
JP4197180B2 (ja) 検体中の内分泌物質測定方法
CA2502976A1 (en) Inflammatory bowel disease and irritable bowel syndrome ibd-first chek diagnostic panel
JP2015517801A5 (ko)
WO2006092729A3 (en) Novel biomarkers for diagnosis and/or prognosis or prognosis of neoplasias in animals
AU2013360685A1 (en) Acute kidney injury
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
US20180299399A1 (en) Electrochemical assay for a protein analyte
WO2016029091A1 (en) Circulating pulmonary hypertension biomarker
WO2009016734A1 (ja) 軽度認知機能障害の検定方法
JP5857385B2 (ja) Ａｐｅ１／ｒｅｆ−１を含有する膀胱癌診断用組成物、及びこれを利用した膀胱癌診断キット
WO2011158769A1 (ja) 非アルコール性脂肪肝炎検出および／または鑑別用マーカー、非アルコール性脂肪肝炎を検出および／または鑑別する方法およびそれらに用いるキット
JP2023511591A (ja) 腸管バリア機能障害および／または肝硬変の検出
JP2011516840A5 (ko)
WO2008067006A3 (en) A method for quantitative detection of diabetes related immunological markers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09817984

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13002224

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 09817984

Country of ref document: EP

Kind code of ref document: A2